Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

NCT04891757 is registered in ClinicalTrials.gov with Foghorn Therapeutics Inc. as lead sponsor.

NCT NCT04891757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04891757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
Lead sponsor
Foghorn Therapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 14, 2021
Completion date
June 30, 2027
Enrollment
144 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hematologic malignancy, refractory acute myeloid leukemia, refractory chronic myelomonocytic leukemia, refractory myelodysplastic syndromes, relapsed acute myeloid leukemia, relapsed chronic myelomonocytic leukemia, relapsed myelodysplastic syndromes